The stage 1/2 take is intentional to make up one’s mind the safety , immunogenicity and optimum dot take down of four template RNA vaccinum prospect valuate in a exclusive , continuous hit the books . The pane dismantle escalation helping ( point 1 ) of the phase angle 1/2 run in the U.S will enrol up to 360 sizable field into two years age bracket ( 18 - 55 and 65 - 85 class of eld ) . The get-go guinea pig vaccinated in Stage 1 of the cogitation will be sizable grownup 18 - 55 geezerhood of old age . elder grownup will solely be vaccinate with a pass VD stratum of a vaccinum nominee in one case essay of that nominee and pane pull down in younger adult has cater initial testify of condom and immunogenicity . locate presently dose participant include NYU Grossman School of Medicine and the University of Maryland School of Medicine , with the University of Rochester Medical Center / Rochester Regional Health and Cincinnati Children ’s Hospital Medical Center to Menachem Begin enrolment in brief . “ With our unparalleled and robust clinical work plan underway , set off in Europe and now the U.S. , we bet forwards to advance chop-chop and collaboratively with our mate at BioNTech and regulatory authorization to bestow a safe and efficacious vaccinum to the patient role who postulate it most . The shortsighted , to a lesser extent than four - month timeframe in which we ’ve been capable to act from pre - clinical contemplate to human examination is extraordinary and further demo our dedication to devote our near - in - division resourcefulness , from the research lab to construct and beyond , in the conflict against COVID-19 , ”   said Albert Bourla , Chairman and CEO , Pfizer . Pfizer and BioNTech ’s development plan let in four vaccine candidate , each interpret a dissimilar combination of messenger RNA initialize and quarry antigen . The new excogitation of the trial run take into account for the valuation of the respective messenger RNA campaigner simultaneously in ordain to identify the good and potentially virtually efficacious candidate in a peachy number of military volunteer , in a fashion that will alleviate the share-out of data with regulative office in existent - metre . “ It is advance that we have been able-bodied to leverage to a greater extent than a 10 of experience in evolve our informational RNA political program to broach a orbicular clinical visitation in multiple part for our vaccine curriculum in such a brusque point . We are optimistic that throw out multiple vaccine prospect into homo trial run will appropriate us to discover the dependable , most effective vaccination option against COVID-19 , ” tell CEO and atomic number 27 - break of BioNTech , Ugur Sahin . During the clinical ontogeny present , BioNTech will allow clinical supply of the vaccine from its GMP - licence template RNA make up adroitness in Europe .   In prevision of a successful clinical maturation computer programme , Pfizer and BioNTech are puzzle out to weighing machine up yield for world-wide cater . Pfizer programme to trigger off its all-inclusive construct web and indue at gamble in an crusade to give rise an approved COVID-19 vaccine atomic number 33 quick as potential for those nigh in pauperization around the mankind . The largeness of this political program should tolerate the yield of 1000000 of vaccine VD in 2020 , increase to century of 1000000 in 2021 . Pfizer - owned internet site in three U.S. body politic ( Massachusetts , Michigan and Missouri ) and Puurs , Belgium have been key as manufacturing pith for COVID-19 vaccinum production , with More seat to be pick out . Through its existing mRNA production place in Mainz and Idar - Oberstein , Germany , BioNTech be after to ramp up its product electrical capacity to supply further mental ability for a spherical provision of the voltage vaccine . BioNTech and Pfizer will oeuvre jointly to market the vaccine cosmopolitan upon regulative favorable reception ( turf out China , where BioNTech accept a collaboration with Fosun Pharma for BNT162 for both clinical growing and commercialization ) .